<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634723</url>
  </required_header>
  <id_info>
    <org_study_id>061501</org_study_id>
    <nct_id>NCT02634723</nct_id>
  </id_info>
  <brief_title>Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A</brief_title>
  <official_title>Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing safety study is to evaluate the safety, immunogenicity,
      and effectiveness of ADVATE in previously untreated patients (PUPs) in China with moderate to
      severe hemophilia A.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of high titer, low titer and transient Factor VIII (FVIII) inhibitors developed</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type of other serious and non-serious adverse events (AEs)</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
    <description>Other AEs refers to AEs other than Factor VIII (FVIII) inhibitors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and type of bleeding episodes treated with ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes treated with 1, 2, 3, â‰¥ 4 infusions of ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) of participants treated prophylactically and on-demand with ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized joint bleeding rate (AJBR) of participants treated prophylactically and on-demand with ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of exposure days (EDs) to ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of ADVATE administered</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of exposure days (EDs) to all Factor VIII (FVIII) products</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of all Factor VIII (FVIII) products administered</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Previously Untreated Patients (PUPs)</arm_group_label>
    <description>PUPs in China with Moderate to Severe Hemophilia A</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octocog alfa (recombinant human coagulation factor VIII)</intervention_name>
    <arm_group_label>Previously Untreated Patients (PUPs)</arm_group_label>
    <other_name>ADVATE</other_name>
    <other_name>Recombinant antihemophilic factor</other_name>
    <other_name>plasma/albumin-free method (rAHF-PFM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previously untreated patients (PUPs) in China with moderate to severe hemophilia A.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously untreated patient (PUP) in China with moderate to severe hemophilia A.

          2. Investigator prescribed ADVATE as the predominant therapeutic agent for the management
             of hemophilia A

          3. Informed consent form from patient and/or legal representative will need to be signed
             per local regulation

        Exclusion Criteria:

          1. Presence of an inherited or acquired hemostatic defect other than hemophilia A, and
             any other clinically significant chronic disease

          2. Participants who participated in another investigational FVIII drug study, or had
             participated in any clinical study involving an investigational FVIII drug during the
             course of the observation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Valentino, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology and Oncology, Harbin The First Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430074</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Children's Hospital Affiliated to Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210019</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Blood Center</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial Hospital of TCM/The First Affiliated Hospital of Zhejiang Chinese Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

